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Abstract
Intracellular circadian clocks, composed of clock genes that act in transcription-translation
feedback loops, drive global rhythmic expression of the mammalian transcriptome and
allow an organism to anticipate to the momentum of the day. Using a novel clock-perturbing
peptide, we established a pivotal role for casein kinase (CK)-2-mediated circadian BMAL1-
Ser90 phosphorylation (BMAL1-P) in regulating central and peripheral core clocks. Subse-
quent analysis of the underlying mechanism showed a novel role of CRY as a repressor for
protein kinase. Co-immunoprecipitation experiments and real-time monitoring of protein–
protein interactions revealed that CRY-mediated periodic binding of CK2β to BMAL1 inhibits
BMAL1-Ser90 phosphorylation by CK2α. The FAD binding domain of CRY1, two C-terminal
BMAL1 domains, and particularly BMAL1-Lys537 acetylation/deacetylation by CLOCK/
SIRT1, were shown to be critical for CRY-mediated BMAL1–CK2β binding. Reciprocally,
BMAL1-Ser90 phosphorylation is prerequisite for BMAL1-Lys537 acetylation. We propose
a dual negative-feedback model in which a CRY-dependent CK2-driven posttranslational
BMAL1–P-BMAL1 loop is an integral part of the core clock oscillator.
Author Summary
The circadian system imposes daily rhythms on behavior, physiology, and metabolism
and allows organisms to anticipate daily recurring changes in the environment. Circadian
clocks are composed of clock genes, acting in transcription–translation feedback loops. At
the heart of this molecular oscillator are the BMAL1–CLOCK transcription factors that
drive expression of Cryptochrome (Cry) and Period genes, which in turn encode inhibitors
of BMAL1–CLOCK–driven transcription. Phosphorylation and other posttranslational
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modifications also specify the activity and stability of clock proteins. Here, we unveiled the
key mechanism underlying the rhythmic phosphorylation of BMAL1 at Ser90 by Casein
Kinase-2 alpha (CK2α). Performing live monitoring of protein–protein interactions, we
show that CRY proteins facilitate cyclic BMAL1–CK2β binding and subsequent cyclic
inactivation of CK2α-mediated BMAL1-S90 phosphorylation; lack of this cyclic event
abolishes circadian rhythmicity. We propose a dual negative-feedback model in which
CRY proteins not only act as inhibitors of BMAL1–CLOCK transcription but also of
BMAL1-S90 phosphorylation.
Introduction
The mammalian circadian system orchestrates a wide variety of metabolic, physiological, and
behavioral rhythms through intracellular clockworks, present in the neurons of the suprachias-
matic nuclei (SCN) and in virtually all other cells and tissues [1]. At the heart of circadian time
keeping is a molecular core oscillator consisting of a set of transcription factors (clock proteins)
that operate in transcriptional–translational feedback loops [1–5] and drive rhythmic expres-
sion of approximately 10% of the mammalian transcriptome [6]. The BMAL1–CLOCK hetero-
dimer is the primary genome-wide driver for transcription of clock genes (including three
period [Per1, 2, and 3] and two cryptochrome [Cry1 and 2] clock genes) and clock-controlled
output genes (CCGs) via binding to E-box containing promoters [7,8]. Periodic association of
Cryptochrome (CRY)–PER complexes with BMAL1–CLOCK after the nuclear translocation of
CRY–PER is facilitated by CLOCK-mediated BMAL1 acetylation, which represses the expres-
sion of E-box clock (controlled) genes and accounts for the negative limb of the circadian feed-
back loop [4]. The BMAL1–CLOCK complex also drives transcription of the retinoic acid
receptor related orphan receptor α (Rorα) and nuclear receptor subfamily 1, group D, member
1 (NR1D1 or Rev-erbα) orphan nuclear receptor genes. RORα and REV-ERBα, after binding to
RORE elements in the Bmal1 promoter, activate and repress Bmal1 transcription and stabilize
the circadian oscillator by driving cyclic expression of Bmal1 [9]. Importantly, to date, only
BMAL1- and CRY1/2-deficient mice exhibit immediate and complete loss in circadian
rhythms [7,10].
Posttranslational modification represents an essential control feature of molecular oscilla-
tors in both prokaryotic and eukaryotic organisms [11] can specify longevity, activity, stability,
and subcellular localization of core clock proteins. Indeed, mammalian clock proteins are
important targets of posttranslational modification events [3–5,12], and their rhythmic phos-
phorylation appears to be a critical step for clock function [8,13–15]. For instance, Rev-erbα
knockout mice (in which cyclic Bmal1 transcription is blunted, but rhythmic BMAL1 modifi-
cation probably remains intact) still exhibit circadian rhythms [16], suggesting that cyclic
BMAL1 modification is more critical in clock machinery than cyclic transcription.
Casein kinase (CK)-2α [17] rhythmically phosphorylates BMAL1 and is pivotal for regu-
lating the mammalian circadian clock [12]. Depletion of CK2α and/or mutation of the
CK2-phosphorylation site in BMAL1 (Ser90), results in impaired circadian nuclear BMAL1
accumulation and impairment of BMAL1–CLOCK–driven rhythmic CCG expression [12].
CK2 is shown to be an indispensable component of the mammalian molecular clock
[12,18,19]. CK2 also phosphorylates PER2 to control PER2 degradation, and depletion of
CK2 results in impaired clock gene oscillation because of lower amplitude of the expression
rhythm and an extended period.
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To date, the molecular mechanism underlying rhythmic mammalian clock protein phos-
phorylation remains elusive. Previously, we have reported circadian BMAL1 phosphorylation
at Ser90 by CK2 [12], which is generally thought to be a constitutively active kinase [20]. Inter-
estingly, the BMAL1 protein is hyperphosphorylated in CRY1/2-deficient mice [8,14], leading
us to hypothesize that CRY proteins are involved in rhythmic BMAL1 modification. Here, we
investigated the universal role and oscillatory mechanism of the circadian CK2-mediated
BMAL1 phosphorylation. Accordingly, a novel role of CRY as a repressor for protein phos-
phorylation was found. We propose a model that explains how CRY proteins produce
circadian oscillations and integrate posttranslational modification events (i.e., BMAL1 phos-
phorylation) in the negative limb of the core transcription–translation feedback loop.
Results
CK2-Mediated Circadian BMAL1-S90 Phosphorylation Regulates
Mammalian Central and Peripheral Clocks
To investigate the critical role of CK2-mediated circadian phosphorylation of BMAL1 at Ser90
(referred to as BMAL1-S90) in regulating the central clock in the SCN and peripheral clocks in
the liver, and in cultured fibroblasts, we designed a competitive inhibitor of BMAL1-S90 phos-
phorylation, consisting of a 14 amino acid BMAL1 peptide (BMs90p), centered around Ser90
(Fig 1Aa). As expected, and in line with S90Amutagenesis data [12], BMs90p dose-dependently
(optimum at ~6 μM) suppressed both the formation of BMAL1 phosphorylated at Ser90 (here-
after referred to as P-BMAL1-S90), andmPer2 promoter-driven luciferase (Per2L) biolumines-
cence rhythms in dexamethasone (Dex) clock-synchronized NIH-3T3 fibroblasts (Fig 1Aa, 1Ab
and 1Ac). P-BMAL1-S90 was recovered only partially around 2-6h post-treatment (S1A Fig). In
contrast, a control peptide with Ser90 replaced by Ala (BMa90p) did not inhibit Per2L rhythms
and P-BMAL1-S90 phosphorylation, demonstrating the specificity of BMs90p (S1B Fig). Thus,
BMs90p perturbs the circadian core oscillator (as evident from the suppressed Per2L rhythms)
by inhibiting BMAL1-S90 phosphorylation. To test the effect on the central and peripheral
clocks, we applied BMs90p to SCN and liver organotypic slices frommPER2Lucmice [21].
BMs90p-treatment provoked an evident reduction of the amplitude (liver; 0.255, SCN; 0.322;
average value pre-treatment set as 1) and peak intensity (liver; 0.420, SCN; 0.525; average value
pre-treatment set as 1) of Per2L (PER2::LUC) rhythms, without any evident phase-shifting
effect (Fig 1B). Notably, this effect was only observed when BMs90p was administered at the
trough of Per2L reporter gene activity (liver; ~CT5, SCN; ~CT2) (S2 and S3 Figs). Similar to the
whole slice data, BMs90p suppressed Per2L rhythms in the SCN, as determined by imaging
multiple (n = 24) small SCN cell clusters (Fig 1C, S4 Fig and S1 Movie). Taken together, these
data strongly suggest a pivotal role of cyclic CK2-mediated BMAL1-S90 phosphorylation in the
circadian oscillator of SCN neurons (central clock) and liver cells (peripheral clocks).
CRY Proteins Inhibit BMAL1-S90 Phosphorylation
How are circadian oscillations in P-BMAL1-S90 levels generated? A clue may be found in pre-
vious observations that BMAL1 is constitutively hyperphosphorylated in CRY1/2-deficient
(CRYdKO) cells with a dysfunctional clock [8,14].
We therefore first investigated whether hyperphosphorylation of BMAL1 in CRYdKO cells
includes Ser90. As shown in Fig 2A and 2B, P-BMAL1-S90 level was significantly higher in
CRYdKO cells than in wild-type (WT) cells. Importantly, expression of Cry1 promoter-driven
Myc-CRY1 in CRYdKO cells (S5 Fig) caused the P-BMAL1-S90 level to return to WT levels
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Fig 1. CK2-mediated circadian BMAL1-Ser90 phosphorylation regulates the central and peripheral clocks. (A) Clock performance and BMAL1
phosphorylation in NIH-3T3:Per2L cells after treatment with BMs90p (a 14 amino acid BMAL1 peptide containing S90; concentrations as indicated) for 30
min and subsequent clock-synchronization by dexamethasone (Dex) treatment for 30 min. (a) Cell cultures were monitored for luciferase activity by real-time
bioluminescence assay. Representative raw (left) and detrended/averaged (right) profiles are shown (n = 4). (b) Immunoblot (IB) analysis of
BMAL1-immunoprecipitates (IP) and lysates from BMs90p-treated cells for BMAL1, P-BMAL1-S90 (Ser90-phoshorylated BMAL1), CK2α, CK2β, and actin
(control). Shown are representative images of triplicate experiments. (c) Quantification of P-BMAL1-S90 levels in BMs90p treated cells (n = 3). Values in
Circadian Oscillatory Mechanism for Mammalian Clock Protein Kinase
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(Fig 2A and 2B), suggesting that the CRY proteins act as suppressors of BMAL1-S90
phosphorylation.
Based on these results, we next focused on CK2-mediated BMAL1-S90 phosphorylation
and the role of CRY proteins therein. Whereas the majority of CK2α catalytic subunits are
untreated cells were set as 1. Error bars indicate standard deviation (SD). (B) Clock performance of organotypic slices of liver and SCN frommPER2Lucmice
following treatment with 6 μMBMs90p or mock treatment with fresh medium around the PER2::LUC trough phase (liver; ~CT [Circadian Time] 5, SCN;
~CT2). (a) Luciferase activity was monitored by real-time bioluminescence imaging. Note the recovery of BMs90P dampened rhythms by medium change.
(b) Quantification of rhythm amplitude and peak bioluminescence after BMs90p treatment (n = 5), in which values in untreated slices are set as 1. Error bars
indicate SD. (C) Clock performance of small cell clusters in organotypic SCN slices from PER2::LUCmice following treatment with 6 μMBMs90p around the
trough phase (~CT2). (a) Luciferase activity was monitored by real-time bioluminescence imaging (n = 24). Shown are detrended (colored lines) and
averaged values (dotted line). (b) Representative examples of bright field (BF) and Per2L images at CT14 (around the peak phase) pre- and post-BMs90p
treatment (day 2 and 4 respectively).
doi:10.1371/journal.pbio.1002293.g001
Fig 2. CRY regulates CK2-mediated BMAL1-Ser90 phosphorylation. (A) Co-immunoprecipitation experiments with non-clock synchronized wild type
(WT) and CRYdKO (Cry1-/-/Cry2-/-) mouse embryonic fibroblasts (MEFs), and CRYdKOMEFs stably expressingmCry1 promoter-driven Myc-CRY1 or CMV-
promoter-driven Myc-GFP (control). IB analysis of BMAL1-, CK2α-, and CK2β-IP and lysates for BMAL1, P-BMAL1-S90, CK2α, CK2β, CRY1, CRY2, and
actin (control). Shown are representative examples of n = 3 experiments. Red arrows indicate the position of major P-BMAL1-S90 (~90 kDa). (B)
Quantification of P-BMAL1-S90 and CK2β–BMAL1 levels. Values in WTMEFs are set as 1. Error bars indicate SD. (C) In vitro analysis of CK2α-mediated
BMAL1-S90 phosphorylation. Mixtures of CK2α and CK2β subunits and GST-BMAL1 were subjected to an in vitro kinase assay. BMAL1-Ser90 kinase
activity was measured by IB analysis with anti-P-BMAL1-S90 (representative examples of n = 3 experiments), and plotted against CK2β/ (GST-) BMAL1
ratio. Values were normalized against activity in the absence of CK2β, which was set as 1. Error bars indicate SD. Note the inhibition of CK2α-mediated
BMAL1-S90 phosphorylation by CK2β.
doi:10.1371/journal.pbio.1002293.g002
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likely recruited to a CK2β (regulatory unit) dimer to form a constitutively active CK2α2β2 tetra-
mer that can phosphorylate a wide range of substrates [20], CK2β behaves as a strong inhibitor
of CK2α-mediated BMAL1 phosphorylation in a dose-dependent manner [12]. Notably, CK2β
does not directly inactivate CK2α [20]. Rather, CK2α activity is thought to fluctuate by the
influence of yet unidentified cellular molecules.
As reported previously [12], we demonstrated that the CK2αmonomer, but not CK2α2β2,
phosphorylates BMAL1 at Ser90, and that CK2 kinase activity dramatically declined at a ratio
of CK2β/CK2α1 (Fig 2C). Similarly, we confirmed that CK2β inhibits CK2α-mediated
BMAL1-S90 in vitro kinase activity as a function of the CK2β/BMAL1 ratio (Fig 2C). Kinase
activity dramatically declined at a ratio of CK2β/BMAL11, suggesting that CK2β interferes
with CK2αmonomer-mediated BMAL1-S90 phosphorylation by direct interaction with
BMAL1. Indeed, in WT cell homogenates, CK2β is shown to co-precipitate with BMAL1 (Fig
2A). In marked contrast, however, BMAL1–CK2β interactions were significantly reduced in
hyperphosphorylated P-BMAL1-S90 containing CRYdKO cells, while the amount of CK2α
bound to BMAL1–CK2β complexes was comparable to that observed in WT cells (Fig 2A and
2B). Taken together, these data suggest that the amount of CK2α interacting with BMAL1 itself
does not reflect the BMAL1 phosphorylation status. Rather, it points to a model in which
CK2β is recruited to BMAL1 to inhibit CK2α activity. In the absence of BMAL1–CK2β interac-
tions in CRYdKO cells, CRY proteins are likely candidates for such recruiting function.
We therefore assessed the binding ability of CK2 subunits to mammalian CRY1/2. In vitro,
recombinant GST-tagged CK2α, α0 and β subunits could pull down CRY1 and CRY2 (S6A
Fig). Thus, both CK2α and β subunits can bind to BMAL1, as well as to CRY1/2. Nonetheless,
consistent with the data shown in Fig 2A, CRY proteins preferentially bind to CK2β. Notably,
CRY1/2 can still interact with CK2β in BMAL1-deficient cells, demonstrating that BMAL1 is
not required for CRY-CK2β interactions (S6B Fig). These results indicate that CRY proteins
mediate BMAL1–CK2β binding by sequentially interacting with CK2β. Moreover, expression
of Myc-CRY1 (resembling native CRY1 in that it also preferentially binds to CK2β; see Fig 2A)
resets the level of BMAL1-bound CK2β to WT levels (Fig 2A and 2B). As the level of BMAL1-
bound CK2α remained unchanged by Myc-CRY1 expression, we propose a model in which
CK2α-mediated BMAL1-S90 phosphorylation is cyclically inhibited by CRY-dependent bind-
ing of CK2β to BMAL1, resulting in rhythmic P-BMAL1-S90 levels.
CRY-Mediated BMAL1–CK2β Association Periodically Suppresses
CK2α-Mediated BMAL1-S90 Phosphorylation to Produce Rhythmic
Kinase
To test our hypothesis that the CRY-dependent periodic binding of CK2β to BMAL1 results in
circadian P-BMAL1-S90 oscillation, we first examined the effects of CRY1/2 deficiency on the
circadian pattern of P-BMAL1-S90 levels. As expected, and in contrast to the robust circadian
oscillations in Dex-synchronized WT cells, P-BMAL1-S90 levels were constitutively expressed
at high levels in CRYdKO cells (Fig 3 and S7 Fig). Moreover, periodic Myc-CRY1 expression
(CRYdKO+CRY1) restored the circadian P-BMAL1-S90 oscillation, which peaked at a similar
time (18–24 h after Dex treatment) as in WT cells (Fig 3B). The levels of BMAL1-bound CK2β
in WT and Myc-CRY1 clock-rescued (CRYdKO+CRY1) cells exhibited robust circadian oscil-
lation with peaks at 6–12 h and approximately 36 h with a phase nearly inverse to that of the
P-BMAL1-S90 oscillation, whereas CRYdKO (with or without GFP) exhibited constitutively
high P-BMAL1-S90 levels (Fig 3A and 3B). Reciprocally, CK2β-IP uncovered a similar tempo-
ral interaction pattern of BMAL1 with CK2β (S7 Fig). Moreover, CRY1 and CRY2 were shown
to co-precipitate with BMAL1 or CK2β in a circadian manner and in phase with BMAL1–
Circadian Oscillatory Mechanism for Mammalian Clock Protein Kinase
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CK2β interactions (Fig 3A and S7 Fig). Notably, the circadian oscillation pattern of CK2β–
CRY1/2 closely matched BMAL1–CK2β, rather than BMAL1–CRY1/2 rhythms (S7 Fig). As
CK2β–CRY1/2 complexes can be formed in the absence of BMAL1 (S6B Fig), these data sug-
gest that CRY proteins periodically facilitate BMAL1–CK2β interaction by first associating
Fig 3. CRY is required for circadian CK2-mediated BMAL1-Ser90 phosphorylation, with inverse phase to BMAL1–CK2β binding rhythm. BMAL1
phosphorylation and CK2β, CRY1, and CRY2 interaction profiles in wild type (WT), CRYdKO (Cry1-/-/Cry2-/-) MEFs (A) and CRYdKOMEFs stably
expressingmCry1 promoter-driven Myc-CRY1 or CMV-promoter-driven Myc-GFP (control) (B). Cells were Dex-synchronized and harvested at 6 h intervals.
BMAL1-IP and lysates were subjected to IB analysis for P-BMAL1-S90, CK2β, CRY1, CRY2 and actin (loading control). Shown are representative examples
of n = 3 experiments (upper panels). P-BMAL1-S90 and BMAL1-bound CK2β, CRY1 and CRY2 levels were quantified and normalized against actin levels
(lower panels). Maximum values in WT/CRYdKO+CRY1 were set as 1. Error bars indicate SD.
doi:10.1371/journal.pbio.1002293.g003
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with CK2β. Moreover, circadian changes in posttranslational modification events may affect
circadian patterns of BMAL1–CRY1/2–CK2β complexes. CK2α/β levels remained constant
over time (S7 Fig), indicating that CK2α/β levels do not determine circadian P-BMAL1-S90
oscillation. These data lead us to conclude that the cyclic phosphorylation of BMAL1-S90 origi-
nates from periodic suppression of CK2α-mediated BMAL-S90 phosphorylation through
CRY-mediated BMAL1–CK2β association.
Live Cell Monitoring Reveals CRY-Enhanced Circadian Oscillation of
BMAL1–CK2β Association
To rule out the possibility of nonspecific associations in pull-down experiments, we next used a
Split Luc complementation assay [22,23] for real-time monitoring of CK2β–BMAL1 interactions
in living cells. In such an assay, bioluminescence can be detected only when N-(ELucN)- and C-
(McLuc1 or ELucC)- tagged proteins associate and allow Luc moieties to complement each other
and form active luciferase (Fig 4A). To this end, we ectopically expressed ELucN-CK2β and
McLuc1/ELucC-BMAL1 in Cos7 and U-2OS cells at a level comparable to that of the native pro-
teins (Fig 4A and 4C).
In Cos7 cells over-expressing Myc-tagged CRY1 or CRY2, bioluminescence due to
BMAL1–CK2β interactions was significantly enhanced (approximately 6-fold; p< 0.001) (Fig
4B). This demonstrates that, consistent with the co-immunoprecipitation data obtained with
CRYdKO-transfected MEFs (see Figs 2 and 3), BMAL1–CK2β binding in living cells requires
CRY1/2. The in vitro CK2β-mediated inhibition of BMAL1-S90 phoshorylation (Fig 2C)
and the BMAL1–CK2β binding in living cells (Fig 4B) strongly indicate that CRY proteins
facilitate BMAL1–CK2β binding and subsequent suppression of CK2α-mediated BMAL1-S90
phosphorylation.
Dex-synchronized U-2OS cells exhibit robust circadian rhythmicity and can express high
levels of ectopic proteins [24]. To investigate temporal changes in BMAL1–CK2β interactions,
we monitored Split Luc activity in real-time mode in U-2OS cells and observed a robust circa-
dian oscillation of BMAL1–CK2β binding, peaking approximately 15 h and 40 h after Dex-syn-
chronization, and as such, inversely phased to P-BMAL1-S90 oscillations (Fig 4C and S8A and
S8B Fig). These P-BMAL1-S90 patterns are consistent with those of asynchronous WT and
CRY1-rescued CRYdKOMEFs (Fig 2A and 2B). As the RREx3/CMV promoter is constitu-
tively active (see S8C Fig), the observed circadian BMAL1–CK2β Split Luc activity originates
from rhythmic BMAL1-CK2β interaction rather than rhythmic BMAL1 expression. Ectopic
expression of BMAL1 and CK2β in the Split Luc assay did not affect endogenous circadian
phase or amplitude of the circadian core oscillator, as monitored through Bmal1-promoter
driven luciferase activity (S9 Fig). Accordingly, the circadian patterns of BMAL1–CK2β associ-
ation monitored by the Split Luc assay represent a nearly endogenous circadian pattern. Taken
together with the result of Figs 3 and 4B, the antiphase circadian oscillations of BMAL1–CK2β
interactions (as revealed by the binding Split Luc assay) and P-BMAL1-S90 rhythms strongly
suggests that under physiological conditions (i.e., in the living cell) cyclic CRY-mediated
BMAL1–CK2β association drives circadian BMAL1-S90 phosphorylation.
CRY1 and BMAL1 Regions Critical for BMAL1–CK2β Association
Next, we generated a panel of ELucC-mBMAL1 deletion constructs (Fig 5A) to determine the
region of BMAL1 [25] critical for BMAL1–CK2β interaction. BMAL1–CK2β binding was
detected at comparable levels in Cos7 cells expressing ELucN-CK2β with either ELucC-B-
MAL1-WT (full length) or deletion mutants in the N-terminal half of BMAL1 (Bd1-3), and
was stimulated by co-expression of CRY1 or CRY2 (Fig 5B). However, irrespective of the
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Fig 4. CRY-enhanced circadian oscillation of BMAL1–CK2β association in living cells. (A) Graphic representation of ELucN-CK2β, McLuc1-BMAL1,
and ELucC-BMAL1 vectors for real-time bioluminescence imaging of CK2β-BMAL1 interactions as monitored by the Split Luc complementation system. IB
analysis with anti-BMAL1 and CK2β antibodies reveals ectopic expression of His-tagged ELucC-BMAL1 (~100 kDa) and ELucN-CK2β ELucN-CK2β (~70
kDa) in Cos7 cells. (B) Cos7 cells were transfected with ELucN-CK2β and ELucC-BMAL1 (2.5 μg), and either Myc-HA-CRY1, Myc-CRY2, or (control) pcDNA
(−) (5 μg). The presence of ectopically expressed CRY1/2 and native CK2αwas confirmed by IB analysis (lower panel). BMAL1–CK2β binding was
monitored by real-time bioluminescence imaging and plotted as the average value of peak bioluminescence levels (n = 5 experiments; upper panel). Error
bars indicate SD. Note that BMAL1–CK2β binding was significantly facilitated by CRY1 and CRY/2. (C) Circadian rhythms in BMAL1–CK2β binding in Dex-
synchronized U-2OS cells were monitored by real-time bioluminescence imaging of Split Luc activity (upper panel). The circadian profiles (Period = 25.3 h,
Acrophase = 15.1 h) (n = 5; blue line) are shown with normalized values to the maximum value that was set as 1. Expression of McLuc1-BMAL1, native
BMAL1, ELucN-CK2β, and native CK2βwas confirmed by IB analysis (upper panel, insets). The circadian profile of P-BMAL1-S90 levels (representative
examples of n = 3 experiments) was determined by IB analysis (lower panel) with anti-P-BMAL1-S90), quantified and normalized to actin content. Maximum
values were set as 1 (upper panel: dotted red line). Error bars indicate SD.
doi:10.1371/journal.pbio.1002293.g004
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Fig 5. Identification of CRY1 and BMAL1 regions involved in CRY-enhanced BMAL1–CK2β binding.
(A) Schematic representation of Split Luc mBMAL1 deletion mutant expression vectors. (B) Cos7 cells were
transfected with ELucN-CK2β and either full length (WT) or mutant (Bd1-5) ELucC-BMAL1, in combination
with either pcDNA (-; negative control), Myc-HA-CRY1, or Myc-CRY2. Expression of ELucC-BMAL1-full
length and deletion mutants (Bd1-5) was confirmed by immunoblot analysis using anti-His antibody (lower
Circadian Oscillatory Mechanism for Mammalian Clock Protein Kinase
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presence of CRY1/2, expression of a BMAL1 mutant protein lacking the CRY-binding domain
(Bd5) [26,27] resulted in significantly lower levels of bioluminescence (approximately 30%;
p< 0.001) as compared to BMAL1-WT (Fig 5B), indicating that the C-terminal region of
BMAL1 is critical for BMAL1–CK2β binding. Yet, BMAL1-Bd5:CK2β Split-Luc activities were
significantly enhanced by co-expression of CRY1 (p< 0.001) or CRY2 (p< 0.001), suggesting
that CRY binding to CK2β can also enhance CK2β binding to BMAL1 without direct physical
interaction between CRY and BMAL1. Moreover, independent of the presence of CRY1/2,
expression of the Bd4 mutant lacking the BMAL1 PAC (PAS-associated C-terminal) domain
resulted in significantly higher levels of bioluminescence (approximately 2-fold; p< 0.001) as
compared to BMAL1-WT (Fig 5B), implicating this region as a potential regulatory site for
BMAL1–CK2β binding. CK2β binding with WT BMAL1, Bd4, and Bd5 was largely enhanced
by ectopic CRY1/2 expression. These findings identified critical regions in BMAL1 for CRY-
enhanced binding to CKβ.
To identify CRY1 protein regions critical for facilitating BMAL1–CK2β interaction, we gen-
erated a panel of mCRY1 deletion constructs (Fig 5C) for co-expression with ELucN-CK2β
and ELucC-BMAL1 in Cos7 cells. CRY-facilitated BMAL1–CK2β binding, as detected by the
Split-Luc assay, was not significantly altered by deletion of either the N-terminal DNA photo-
lyase domain (Cd1) or the C-terminal region (Cd4) of CRY1 (Fig 5D). However, co-expression
of a CRY1 mutant protein lacking the FAD-binding domain (Cd2) [28] resulted in significantly
lower levels of bioluminescence (approximately 20%; p< 0.001) as compared to CRY1-WT
(Fig 5D), indicating that the FAD-binding domain of CRY1 is critical in enhancing BMAL1–
CK2β binding. Notably, co-expression of a mutant CRY1 protein (Cd3), lacking the pivotal
region for inhibition of BMAL1–CLOCK-mediated transcription in the FAD-binding domain
[28,29] also resulted in significantly lower levels of bioluminescence (approximately 40%;
p< 0.001) as compared to CRY1-WT (Fig 5D). This finding indicates that the FAD-binding
region is not only critical for suppression of CLOCK–BMAL1 -mediated transcription activa-
tion but also for CK2α-mediated BMAL1-S90 phosphorylation by facilitating BMAL1–CK2β
binding.
BMAL1-K537 Acetylation Reduces BMAL1-S90 Phosphorylation via
Enhancing BMAL1–CK2β Association
BMAL1-K537 acetylation has been shown to facilitate the recruitment of CRY1/2 to BMAL1
[4]. To examine whether BMAL1-K537 acetylation affects S90 phosphorylation and CRY-
mediated BMAL1–CK2β binding, we first stably transfected Bmal1-/- knockout MEFs with a
mBmal1 promoter-driven wild type (Myc-BMAL1-WT) or acetylation mutant BMAL1 (Myc-
BMAL1-K537R) expression construct. BMAL1-K537R retains the ability for S90 phosphoryla-
tion (S10 Fig), indicating that K537 acetylation is not prerequisite for S90 phosphorylation. S90
phosphorylation levels were even higher for BMAL1-K537R than for BMAL1-WT. Interest-
ingly, CK2β and CRY1/2 binding to BMAL1-K537R was reduced as compared to BMAL1-WT
panel). BMAL1–CK2β binding was monitored by a real-time bioluminescence imaging (upper panel). Shown
are averaged peak bioluminescence values (n = 6 experiments). Error bars indicate SD. (C) Schematic
representation of mCRY1 deletion mutant expression vectors. (D) Cos7 cells were transfected with
ELucN-CK2β and ELucC-BMAL1, in combination with either full length (WT) or mutant (Cd1-4)
pcDNA-FLAG-CRY1. Expression of CRY1-full length and deletion mutants (Cd1-4) was confirmed by
immunoblot analysis using FLAG antibody (lower panel). BMAL1–CK2β binding was monitored by a real-time
bioluminescence imaging (upper panel). Shown are averaged peak bioluminescence values (n = 6
experiments). Error bars indicate SD.
doi:10.1371/journal.pbio.1002293.g005
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(S10 Fig), suggesting that K537 acetylation is required for CRY-mediated recruitment of CK2β
to BMAL1.
Next, we performed a Split-Luc live cell assay experiment using an ElucC-mBMAL1-K537R
mutant protein. In the absence of CRY1/2, the BMAL1-K537R–CK2β binding was not signifi-
cantly different from BMAL1–CK2β binding. However, in the presence of CRY proteins
BMAL1–CK2β interactions increased by approximately 4-fold, while BMAL1-K537R–CK2β
binding did not significantly increase (p< 0.001 in comparison withWT) (Fig 6A). Thus,
CLOCK-mediated acetylation of K537 in the C-terminal region of BMAL1 appears critical for
CRY-enhanced BMAL1–CK2β binding.
To further investigate whether BMAL1-K537 acetylation up-regulates BMAL1–CK2β bind-
ing and subsequently represses BMAL1-S90 phosphorylation, we utilized a mouse fibroblast cell
line deficient in silent information regulator 1 (SIRT1), a member of the sirtuin family of NAD
+-dependent histone deacetylases (HDACs) that also targets acetyl BMAL1-K537 [30]. As pre-
viously reported [30], the acetyl-BMAL1-K537 level was substantially higher in SIRT1KO
(Sirt1-/-) MEFs than inWTMEFs (Fig 6Ba). Importantly, as predicted, P-BMAL1-S90 levels
were significantly reduced in SIRT1KOMEFs (approximately 50% of control; p< 0.001) as
compared to WT cells (Fig 6Bb). Consistently, BMAL1–CK2β binding was significantly
increased (approximately 330% of control; p< 0.01) in SIRT1KOMEFs (Fig 6Bb). Consistent
with our previous report [4,30], BMAL1–CRY1/2 binding was increased in SIRT1KOMEFs
(Fig 6Bb).
Taken together, these data demonstrate that acetylation of BMAL1 at Lys537 facilitates
BMAL1–CK2β association, and as such represses BMAL1-S90 phosphorylation.
BMAL1-S90 Phosphorylation Is Prerequisite for BMAL1-K537
Acetylation and Subsequent Recruitment of CRY to BMAL1
For a variety of proteins phosphorylation has been shown to trigger subsequent acetylation
events [31,32]. Accordingly, S90 phosphorylation is potentially involved in the regulation of
BMAL1 acetylation. To assess the link between BMAL1-S90 phosphorylation and BMAL1-K537
acetylation and to further establish the integral role of the CK2-mediated BMAL1-S90 phos-
phorylation in the circadian core oscillator, we examined the effect of BMAL1-S90 mutation on
BMAL1-K537 acetylation, which, as shown above, is, critical for CRY-mediated BMAL1–CK2β
binding and P-BMAL1-S90 rhythms.
To this end, we stably expressed wild-type BMAL1 (BMAL1-WT), mutant BMAL1-S90A
(with Ser90, located in the basic helix-loop-helix DNA binding motif, substituted for Ala) or
GFP (negative control) in MEFs derived from clock-deficient Bmal1-null mice [7]. As shown in
Fig 7A, Myc-BMAL1-WT andMyc-BMAL1-S90A were expressed at equal level. The acetylation
level of BMAL1-S90A was dramatically reduced as compared to BMAL1-WT (approximately
20% of control; p< 0.001; Fig 7A and 7B). Thus, CK2α-mediated BMAL1-S90 phosphorylation
might be a prerequisite for CLOCK-mediated BMAL1 K537 acetylation. Consistent with this
notion, BMAL1–CLOCK levels were decreased (approximately 50% of control; p< 0.002) by
the S90A mutation (Fig 7A and 7B), suggesting that reduction in BMAL1–CLOCK association
is the cause of the reduced BMAL1-K537 acetylation level.
Furthermore, the BMAL1–CRY1/2 interactions were also significantly decreased by the
S90A mutation (Fig 7A and 7B), indicating that S90 phosphorylation is prerequisite for
K537-facilitated CRY recruitment to BMAL1. As previously reported, reduction of BMAL1–
CRY interactions by K537R mutation demonstrates K537-acetylation-dependent recruitment
of CRY1/2 to BMAL1 [4]. Thus, CK2α-mediated BMAL1-S90 phosphorylation is a prerequi-
site for CLOCK-mediated BMAL1-K537 acetylation, subsequent CRY1/2 recruitment to
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Fig 6. BMAL1-K537 acetylation reduces BMAL1-S90 phosphorylation via enhancing BMAL1–CK2β
association. (A) Reduced CRY-enhanced CK2β binding to mutant BMAL1-K537R, lacking a CLOCK-
mediated acetylation site. As in Fig 5, except that an acetylation mutant ELucC-BMAL1 vector (K537R) was
used. (B) Reduction of CK2-mediated BMAL1-S90 phosphorylation in SIRT1KO (Sirt1-/-) cells, lacking the
major clock-regulating deacetylase SIRT1. (a) Co-immunoprecipitation experiments with WT and SIRT1KO
MEFs 23h after Dex treatment. IB analysis of BMAL1-IP and lysates for P-BMAL1-S90, CK2β, acetyl-BMAL1,
SIRT1, BMAL1, and actin. Shown are representative examples of n = 3 experiments. (b) Quantification of
P-BMAL1-S90 and BMAL1-bound CK2 β levels. Values in WTMEFs are set as 1. Error bars indicate SD.
doi:10.1371/journal.pbio.1002293.g006
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BMAL1 and CRY1/2-facilitated BMAL1–CK2β binding to regulate negative feedback suppres-
sion of clock gene expression and CK2α-mediated BMAL1-S90 phosphorylation, respectively.
Our results do not exclude the existence of other BMAL1 phosphorylations, which directly trig-
ger BMAL1-acetylation and other modifications, located downstream of CK2-mediated
BMAL1-S90 phosphorylation.
Discussion
Circadian BMAL1-S90 phosphorylation has been shown to be an important regulatory step in
the mammalian core clock oscillator [12]. In the present study, we addressed the underlying
mechanism and uncovered a vital interplay between CRY proteins and circadian BMAL1 phos-
phorylation. First, by applying a novel clock-perturbing peptide (BMs90p) to SCN and liver
organotypic slices frommPER2Luc mice and subsequent live monitoring of circadian clock per-
formance, we further highlighted a universal critical role of BMAL1-S90 phosphorylation in
central and peripheral clocks. BMs90p (a small 14 amino acid peptide containing the BMAL1-
Ser90 phosphorylation site targeted by CK2) behaves as a competitive inhibitor of BMAL1-S90
phosphorylation and was shown to reversibly blunt Per2L bioluminescence rhythms in a dose-
and circadian time-dependent manner
Next, triggered by the observation that a CRY1/2-deficiency causes hyper-phosphorylation
of BMAL1 [8,14], we focused on the molecular mechanism underlying circadian BMAL1-S90
phosphorylation and showed that in wild-type cells, circadian phosphorylation of BMAL1-S90
is accompanied by inverse phase cyclic association of BMAL1 with CK2β, a known inhibitor of
CK2α-mediated BMAL1 phosphorylation [12]. Notably, a CRY1/2-deficiency abolishes
Fig 7. BMAL1-S90 phosphorylation is prerequisite for BMAL1-K537 acetylation and subsequent recruitment of CRY to BMAL1. (A) Bmal1−/−MEFs
stably expressingmBmal1 promoter-driven Myc-BMAL1-WT (wild type), Myc-BMAL1-S90A (CK2−phosphorylation site-deficient mutant), and CMV-
promoter-driven Myc-GFP (control) were Dex-synchronized. The supernatants from the cells harvested 22 h after treatment were subjected to Myc-BMAL1
IP. The Myc-BMAL1 IPs and total lysates (Load) were subjected to IB analysis for Acetyl-BMAL1 and BMAL1- co-immunoprecipitated (Co-IP) CRY1/2 and
CLOCK. (B) Normalized Acetyl-BMAL1 and BMAL1-bound CRY1/2 and CLOCK levels are shown in the graph (n = 3 experiments) and error bars indicate
SD.
doi:10.1371/journal.pbio.1002293.g007
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BMAL1-CK2β interactions, and as such prevents cyclic inhibition of BMAL1-S90 phosphory-
lation, resulting in constitutively hyperphosphorylated BMAL1. P-BMAL1-S90 in CRY1/2
deficient cells could be rescued by rhythmic Cry1 expression, which points to a model in which
CRY proteins cyclically recruit CK2β to BMAL1 to inhibit CK2α activity.
To provide further evidence for this model, we developed a Split-Luc–based assay system
for real-time monitoring of clock protein–protein interactions in living cells. Using this assay,
we have shown that BMAL1 cyclically binds to CK2β and that circadian BMAL1–CK2β bind-
ing is enhanced by CRY proteins. Moreover, using the same Split-Luc approach in combination
with mutant versions of the BMAL1 protein, we have shown that the PAC and CRY-binding
domains in the C-terminal region of BMAL1, as well as BMAL1-K537 acetylation (known to
enhance CRY-recruitment to BMAL1 [4]) are important in regulating BMAL1–CK2βbinding.
Indeed, using SIRT1KO cells, we demonstrated that BMAL1-K537 hyper-acetylation reduces
BMAL1-S90 phosphorylation through enhanced CRY-driven BMAL1–CK2β association. As
BMAL1-S90 phosphorylation is prerequisite for BMAL1-K537 acetylation (see below), the low
but significant P-BMAL1-S90 level in SIRT1KOMEFs is apparently sufficient to trigger
BMAL1-K537 acetylation (Fig 6B). Reciprocally, BMAL1-S90A expressing MEFs, lacking
BMAL1-S90 phosphorylation, cannot trigger significant BMAL1-K537 acetylation (Fig 7A
and 7B).
By BMAL1-S90A mutagenesis, we showed that BMAL1-S90 phosphorylation is prerequisite
for BMAL1-K537 acetylation. The S90A mutation significantly reduces the nuclear BMAL1–
CLOCK levels [12,33] and S90-phosphorylated BMAL1 is mostly detected in the nuclear frac-
tion (S11 Fig), strongly suggesting BMAL1 enters the nucleus promptly after S90 phosphoryla-
tion. Taken together with the lower K537 acetylation and CLOCK binding capacity of
BMAL1-S90A, as compared to BMAL1-WT, it is assumed that K537 acetylation mainly occurs
after BMAL1–CLOCK nuclear entry. The enhanced K537 acetylated/S90-phosphorylated
BMAL1 level in Sirt1 knockout cells suggests a mutual regulatory loop between K537 acetyla-
tion and S90 phosphorylation and supports the notion that S90 phosphorylation is prerequisite
for K537 phosphorylation, while K537 acetylation represses S90 phosphorylation.
In conclusion, we established a circadian clock-controlling role of CK2 kinase, formerly
thought to be a constitutively active kinase [20] in BMAL1 phosphorylation and uncovered a
novel role of CRY as a regulator of cyclic CK2-mediated BMAL1 phosphorylation. Fig 8 illus-
trates our model for the molecular mechanism of the CK2-mediated posttranslational loop and
its role in regulating the intracellular circadian core oscillator. In this model, cyclic CK2α-
mediated BMAL1-S90 phosphorylation serves as the periodic gateway that controls BMAL1–
CLOCK heterodimerization (step I) and time-delayed nuclear accumulation of BMAL1–
CLOCK (step II) [12]. Step I and II may play a critical role in the events described below and
serve as a time-delay factor that fine-tunes the circadian periodicity [14]. Therefore, we refer to
CK2-mediated BMAL1-S90 phosphorylation as the first gate, probably located at the boundary
between the cytoplasm and nucleus. Consistently, constitutive nuclear predominant BMAL1
localization in CRYdKOMEFs through the circadian cycle might be largely due to constitutive
active BMAL1-S90 phosphorylation [14]. After BMAL1–CLOCK accumulates in the nucleus,
E-box promoter containing clock genes, including CRY1/2, are temporally transactivated (step
III). This is followed by negative feedback suppression of BMAL1–CLOCK transcription of E-
box genes by the recruitment of CRY1/2 to BMAL1 (step IV), which is regulated by CLOCK-
mediated BMAL1-K537 acetylation [4] and requires phosphorylated BMAL1-S90. In the next
step (step V), because of the delayed surge in CRY1/2–CK2β binding, the BMAL1–CLOCK–
CRY complex is released from the E-box. Thereafter, we hypothesize that CRY proteins are
released from the complex to make way for newly incoming CRY1/2–CK2β complexes that
bind to BMAL1–CLOCK via direct CRY–BMAL1 interaction. Deletion of the CRY-binding
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Fig 8. A CRY-based dual negative feedbackmodel integrating the BMAL1– P-BMAL1 loop with the circadian core oscillator. Proposed model for
CRY-CK2β–mediated circadian rhythms in BMAL1 phosphorylation by CK2α (the BMAL1–P-BMAL1 loop) as an integral part of the circadian core oscillator.
In short, upon phosphorylation of BMAL1-S90 by CK2α (step I), BMAL1 binds to CLOCK (step II) to form a transcriptional activator complex for transcription
of E-box promoter containing clock genes (i.e., Cry and Per genes) and clock-controlled genes (step III). CK2α remains bound to BMAL1 in a catalytically
active state (as indicated by the red color). After a delay, CRY proteins will bind to the CLOCK–BMAL1–CK2α complex to inhibit E-box gene transcription
(step IV). Upon dissociation of the BMAL1–CLOCK–CRY–CK2α complex from the DNA, CRY is released from the complex to allow CRY–CK2β binding, and
subsequent BMAL1–CK2β binding, resulting in the formation of BMAL1–CLOCK–CRY–CK2β–CK2α complex (step V). This step, triggered by acetylation of
BMAL-K537, renders CK2α inactive (as indicated by the grey color). After dissociation of the BMAL1–CLOCK–CRY–CK2β–CK2α complex, BMAL1 is
degraded and/or dephosphorylated and deacetylated (step VI) to start a new cycle. For a detailed description of the model, see the Discussion section. For
simplicity, PER proteins have not been included in the model and CRY1 and CRY2 proteins are collectively shown as CRY.
doi:10.1371/journal.pbio.1002293.g008
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domain in BMAL1 does not completely abolish CRY-mediated enhancement of BMAL1–
CK2β binding in the Split Luc assay (Fig 5), suggesting direct BMAL1–CRY interaction is not
absolutely necessary for the enhancement of BMAL1–CK2β binding. Given that CRY has also
been shown to bind to CLOCK [29], docking of CRY–CK2β to BMAL1–CLOCK may also
involve CRY–CLOCK interactions. Through formation of CRY1/2–CK2β intermediates,
CRY1/2 facilitates BMAL1–CK2β association. Notably, the release of CRY from and re-entry
of CRY–CK2β in the BMAL1–CLOCK complex (instigated by the observation that CRY can
bind CK2β in the absence of BMAL1) is the most speculative step in the model. In the absence
of experimental/mechanistic evidence we cannot fully exclude that CRY proteins enhance
BMAL1–CK2β binding while still bound to the BMAL1–CLOCK–CRY complex.
In vitro, CK2β can bind to BMAL1 in the absence of CRY and inhibit BMAL1-S90 phos-
phorylation by CK2α (Fig 2C and S6A Fig). Under these non-physiological conditions, inhibi-
tion of S90 phosphorylation may occur through (simultaneous) formation of CK2β-BMAL1
complexes that prevent CK2α from binding to BMAL1, and/or formation CK2α2β2 tetramers
[20], which are probably incapable of phosphorylating BMAL1 [12]. However, as formation of
a CK2α2β2 tetramer requires formation of a CK2β dimer that subsequently binds two CK2α
monomers, and as in vitro BMAL1-S90 phosphorylation by CK2α is maximally inhibited at a
CK2β:BMAL1 ratio of 1 (Fig 2C), interaction of 1 CK2βmonomer rather than a tetramer with
1 BMAL1 molecule appears sufficient to inhibit S90 phosphorylation. In vivo, BMAL-CK2β
association appears to block (BMAL1-bound) CK2α activity, rather than BMAL1–CK2α asso-
ciation, and requires the help of CRY proteins. Although we do not exclude a model in which
CK2β is included in the BMAL1–CLOCK–CRY–CK2β–CK2α as a dimer or α2β2 tetramer
complex, we consider inhibition of CK2α-mediated BMAL1-S90 phosphorylation by a CK2β
monomer the most plausible option (step V). Taken together, inverse-phased circadian
BMAL1–CLOCK–CRY–CK2β−CK2α complex formation might be the primary determinant
for circadian CK2α-mediated BMAL1-S90 kinase activity. Next, S90 phosphorylated BMAL1
undergoes a SIRT1-mediated deacetylation step (step VI) [30] that likely liberates BMAL1
from the complex. Subsequent SUMOylation [3] and ubiquitination [34] of BMAL1 may target
the protein for proteasomal degradation. In addition, non-degraded BMAL-S90 needs to be
dephosphorylated by yet unknown phosphatases to initiate a new cycle through CK2α-medi-
ated phosphorylation of BMAL1.
BMAL1-S90 phosphorylation by the CK2αmonomer most likely occurs at step I (Fig 8).
S90-phosphorylation of BMAL1 takes place in the cytoplasm and triggers CLOCK binding and
subsequent BMAL1–CLOCK nuclear accumulation [12]. We have shown that BMAL1–CK2α
complexes exist throughout the circadian cycle (S7 Fig). This suggests that the CK2αmonomer
remains bound to the BMAL1–CLOCK complex up to step IV. Likely, CK2α remains catalyti-
cally active (though its substrate is no longer available) and only gets inactivated after CRY-
mediated binding of CK2β (step V).
In this study, we have unveiled the underlying mechanism for the cyclic CK2-mediated
BMAL1 phosphorylation as a critical event in the mammalian circadian core clock machinery.
BMAL1–P-BMAL1 loop forms a distinct interlocked loop in the clock machinery (step I, V,
and VI) and have integral roles in the core circadian oscillator through periodic CRY-mediated
negative feedback suppression. In this scenario, CRY proteins have a dual function. Strikingly,
in addition to their known function as repressors of BMAL1–CLOCK-driven transcription,
we found a novel role of CRY proteins as a repressor of CK2 protein kinase activity toward
BMAL1-S90. Notably, we observed that the FAD binding region of CRY1, known to be essen-
tial for repression of BMAL1–CLOCK-driven transcription [28], is also critical for inhibition
of CK2α-mediated BMAL1-S90 phosphorylation.
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Interestingly, CLOCK-mediated BMAL1-K537 acetylation [4], through sequential recruit-
ment of CRYs and then CRY1/2–CK2β to the BMAL1–CLOCK complex, acts as a common
molecular key for evoking CRY-mediated feedback inhibition of BMAL1–CLOCK transcrip-
tion activity and CRY-dependent suppression of BMAL1 phosphorylation. Ultimate verifica-
tion of our model ideally requires in vitro reconstitution of the CRY-driven circadian BMAL1–
P-BMAL1 loop, as shown for cyanobacterial KaiC phosphorylation [35]. In a first experiment
in which purified recombinant CRY1 was added to the in vitro BMAL1-S90 phosphorylation
assay (as performed in Fig 2C), we observed that despite its ability to bind BMAL1 (S12A Fig),
CRY1 could not inhibit CK2α-mediated BMAL1-S90 phosphorylation (S12B Fig). This appar-
ent difference markedly contrasts with the in vivo data, where CRY has been shown pivotal for
CK2β-mediated inhibition of BMAL1-S90 phosphorylation by CK2α. Clearly, in vitro assays
differ from the in vivo situation in that they do not take into account the effect of subcellular
localization of the proteins studied, their interaction with DNA or chromatin, or the involve-
ment of other protein partners. Moreover, in vitro synthesized proteins probably do not
undergo posttranslational modification, leading us to hypothesize that CRY can only recruit
CK2β to BMAL1 after acetylation of BMAL1-K537.
CK2 phosphorylates a large array of cellular proteins and is widely involved in regulating
mammalian physiology [17]. However, temporal aspects of CK2 function are still elusive.
Therefore, in addition to its role in the core clock, future investigations should focus on
CK2-mediated circadian signaling as a regulator of various physiological and pathological
pathways. A genome-wide phospho-proteomics study of periodic signaling systems focused on
CK2 may help elucidate the chronobiological attributes of diverse physiological events and
facilitate the development of therapies for circadian-system–related disorders [36], such as
metabolic syndromes, cancer, and neuropsychiatric diseases. Recently, we demonstrated that
CK2-BMAL1 kinase plays a critical role in controlling protective pathways evoked by reactive
oxygen species and is crucial for preventing oxidative-stress–related diseases [37].
Materials and Methods
Biochemical Analysis
Immunoprecipitation and immunoblotting were performed using sample solutions as previ-
ously described [4,12,14]. Antibodies utilized in the immuno-detection assays included anti-
BMAL1 [14], PER1, BMAL1-phospho-Ser90 (P-BMAL1-S90) and BMAL1-acetyl-Lys537
(Acetyl-BMAL1) previously generated in our laboratories [12,30], CK2β (Calbiochem, San
Diego, CA, United States), CK2α, actin, RNA polymerase II (Santa Cruz. Biotechnology Inc.,
Santa Cruz, CA, US), Myc-tag (Upstate Biotechnology Inc., Lake Placid, NY, US), CLOCK
(Affinity BioReagents, Golden, CO, US), CRY1 (kindly donated by Dr. Todo), CRY2 [14], His-
tag, FLAF-tag (MBL Co. Ltd., Nagoya, Japan), and HRP-conjugated anti-rabbit/goat/mouse
IgG (Zymed, South San Francisco, CA, US). Immunoblot data were quantified by computer-
ized densitometry and statistical analysis were performed as described previously [12,14,38].
The density of the protein bands was normalized to actin levels and the value of the control
sample was set as 1. Statistical analysis was performed using the Student’s t test. Calculated
error bars indicate standard deviation (SD).
In vitro kinase assays were performed as described previously [12,13], using CK2 subunits, 1
mMATP, and GST-BMAL1, with/without His-CRY1 (see below). CK2α, CK2β, and GST-
BMAL1 were prepared as described previously [12]. Kinase activities were measured by immu-
noblot using an anti-P-BMAL1-S90 antibody, and quantified as described above. Immunoblot
and kinase assay data were normalized to the control values.
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GST-CK2α, α’, and β subunits were expressed in bacteria, purified and analyzed by CBB
staining. Mammalian clock proteins labeled with 35S-methionine were produced using the
TNT Quick Coupled Transcription/Translation system (Promega) with expression vectors for
BMAL1 (donated by Dr. Ikeda) and V5-CRY1/2 (donated by Dr. Reppert). CK2 subunits and
clock proteins were mixed (combinations as indicated in the text), incubated, and affinity-pre-
cipitated with glutathione Sepharose beads. Recombinant His (and V5)-tagged CRY1 protein
was expressed in High Five insect cells using pIB/V5-His vector and InsectSelect System (Invi-
trogen, CA, US). His-CRY1 protein was purified using Talon-resin (Clontech, CA, US).
Plasmid Construction
The plasmid vector pGL4-Per2, constructed to express the ~1.7 kbmPer2 promoter-driven
luciferase construct (Per2-Luc), has been described previously [12]. The vector pGL4-Bmal1
was constructed to express the ~1 kbmBmal1 promoter-driven luciferase. The pcDNA (Invi-
trogen, Carlsbad, CA, US)-based vectors Myc-HA-mCRY1, Myc-mCRY2, FLAG-mCRY1 and
the deletion mutants (Cd1–4; Fig 5C) were constructed to express CMV promoter-driven
CRY1/2.
Retroviral expression vectors (pCLNCX) for the ~1.6 kbmPer3 promoter [39]-driven lucif-
erase (Per3-Luc) and the ~1 kbmCry1 promoter-drivenMyc-CRY1 and CMV-promoter-driven
GFP constructs have been described previously [12]. In addition, these experiments utilized
previously prepared expression constructs formBmal1-promoter-driven BMAL1-WT/mutants
and CMV-promoter-driven GFP [4,12].
For the Split Luc complementation assay [23], the cDNA of Emerald Luciferase (ELuc) was
obtained from Toyobo Co. Ltd. (Osaka, Japan). The multiple complement luciferase fragment
cDNA construct (McLuc1) was generated as described previously [22]. The full-length mouse
BMAL1 and human CK2β cDNAs were ligated downstream of the C-terminal (McLuc1 or
ELucC) and N-terminal (ELucN) luciferase fragments, respectively (Fig 4A). Full-length
BMAL1, BMAL1 deletion mutants (Bd1–5; Fig 5A), and CK2β cDNAs, were ligated down-
stream of ELucC and ELucN, respectively. Each cDNA fragment was amplified by polymerase
chain reaction (PCR) and inserted into pcDNA4/V5-His (B) or pcDNA3.1 (Invitrogen, Carls-
bad, CA, US) vector backbones using multiple cloning sites. In the ELucC/McLuc1-BMAL1
expression vector, three repeats of the BMAL1 Rev-erbA/ROR binding element (RRE) were
added. To test promoter performance, the McLuc1-BMAL1 and ELucN-CK2β coding
sequences were replaced by Luc (from pGL4), giving rise to the RREx3-CMV-Luc and
CMV-Luc expression vectors. The sequences of all expression vectors were checked using a
genetic analyzer (ABI310; Applied Biosystems, Foster City, CA, US). For long-lasting (stable)
expression of the plasmids in human cells, episomal-type vectors were constructed by replace-
ment of the CAG-promoter-MCS in pEBMulti-Hyg (Wako, Osaka, Japan) with CMV-E-
LucN-CK2β and RREx3-CMV-McLuc1-BMAL1 constructs. The expression vectors were
purified with the PureLink HiPure Plasmid Filter Midiprep Kit (Invitrogen, Carlsbad, CA, US)
prior to transfection of mammalian cells.
Cell Culture, Real-Time Bioluminescence Analysis, and Data
Processing
Established (NIH-3T3) and primary (MEF) mouse embryonic fibroblasts, and human osteo-
sarcoma (U-2OS) cells were cultured as previously described [12,24,30,37]. BMAL1-deficient
(KO) MEFs [7] were kindly donated by Dr. Bradfield. For clock synchronization, cells were
treated with 0.1 μM dexamethasone (Dex) for 2 h. DNA transfection was performed using
FuGENE HD according to manufacturer’s protocol (Roche Diagnostics Basel, Switzerland).
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The peptides BMs90p (RRDKMNSFIDELAS, a 14 amino acid BMAL1 peptide centered
around BMAL1 Serine 90) and BMa90p (RRDKMNAFIDELAS, a negative control peptide
with serine 90 replaced by alanine) were custom-made by Gen Script (Piscataway, NJ, US).
Peptides were dissolved in water and applied to actively growing cultured cells at60% conflu-
ence. The RetroMax expression system (Imgenex, San Diego, CA, US) was used to produce ret-
rovirus for the rescue experiment. Retroviral infection was performed as previously described
[12]. Real time bioluminescence activities were monitored using the Kronos Dio system
(ATTO, Tokyo, Japan) as previously described [37].
All animal experiments were approved by the Toho University Animal Committee, and car-
ried out under the control with Guidelines for Proper Conduct of Animal Experiments by Sci-
ence Council of Japan.mPER2Luc mice (B6.129S6-Per2tm1Jt/J)21 were purchased from Jackson
Laboratories (Bar Harbor, ME, US) and maintained at 25°C on a 12 h light/dark (LD) cycle
(light: zeitgeber time [ZT] 0–12; dark: ZT 12–24). Preparation of organotypic slices from 4–8
week old mice, real-time bioluminescence assay, and microscopic imaging analysis (using the
LV200 Bioluminescence Imaging System; Olympus, Tokyo, Japan) and MetaMorph analysis
(MetaMorph, Nashville, TN, US) were performed using previously published procedures [40],
briefly described below. The reduction of the peak (Fig 1Bb) was quantified by evaluating the
difference in peak values in Fig 1Ba over 2 d before and after BMs90p treatment. The reduction
of rhythm amplitude (Fig 1Bb) was quantified by comparing peak and trough values in the
detrended data (S3 Fig) over 2 d before and after BMs90p treatment.
Values obtained from bioluminescence analyses were normalized by the maximum peak
intensities over time and further normalized by the averaged intensity over time, as described
previously [37,41]. Real-time bioluminescence in cell cultures and organotypic slices treated
with 0.2 mM Luciferin (Toyobo) were monitored using the Kronos Dio system with acquisition
times of 2 (promoter-Luc assays) or 3 min (Split-Luc assays), according to the manufacturer’s
protocol. Values were obtained from each sample in a given experiment using the same detec-
tors. The n-values indicated for each experiment refer to the number of samples analyzed with
the same detectors in the same experiments. The y-axis label “Bioluminescence” indicates that
the relative photo-counting values reflect arbitrary units (a.u.) from raw data; “RLU” (Relative
Light Units) indicates that the relative photo-counting values were normalized by averaging
intensity over time. The y-axis label “Deviation from the moving average” indicates that the
values were detrended according to the Kronos Dio instrument protocol (ATTO). In many
cases, as indicated in the figure legends, detrended values were further normalized by averaging
intensity over time. The data in these graph labeled "deviation from the moving average” were
further normalized using maximum circadian peak intensities over time. Real-time biolumi-
nescence for microscopic imaging was monitored using the LV200 microscope with acquisition
times of 48 min (EM-gain = 400) according to the manufacturer’s protocol (Olympus). Values
obtained from each tracked region of interest (ROI) surrounding neighboring small clusters of
cell-areas were processed similarly.
Statistical Analyses
We used factorial design analysis of t test to analyze data as appropriate. The data presented in
this study represent the average of multiple experiments, as specified in the figure legends.
Supporting Information
S1 Data. Values for the quantitative experiments corresponding to main figures. Data from
the quantitative/statistical analysis are shown with respect to the graphs in Figs 1–7. Data
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includes p-values for the statistical significance.
(XLSX)
S2 Data. Values for the quantitative experiments corresponding to supporting figures.
Data from the quantitative/statistical analysis are shown with respect to the graphs in S1–S5,
S8 and S9 Figs. Data includes p-values for the statistical significance.
(XLSX)
S1 Fig. Characterization of BMs90p. (A) BMAL1-IPs and lysates from untreated (-) and
BMs90p (6 μM) treated NIH-3T3 cells were subjected to IB analysis for BMAL1,
P-BMAL1-S90, CK2α, and CK2β, using actin as a loading control. Representative images of
duplicate experiments are shown. (B) Clock performance and BMAL1 phosphorylation in
NIH-3T3:Per2L cells after treatment with 6 μM BMs90p (S90p) and BMa90p (a peptide
replaced Ser90 to Ala) for 30 min and subsequent clock-synchronization by dexamethasone
(Dex) treatment for 30 min. (a) Cell cultures were monitored for luciferase activity by real-time
bioluminescence assay. Representative raw (left) and detrended/averaged (right) profiles are
shown (n = 3). (b) Immunoblot (IB) analysis of BMAL1-IP and lysates from untreated (-) and
S90p/A90p (6 μM) treated cells for BMAL1, P-BMAL1-S90 (Ser90-phoshorylated BMAL1),
CK2α, CK2β, and actin (loading control).
(EPS)
S2 Fig. Effect of BMs90p-treatment on circadian rhythms in PER2::LUC liver and SCN
organotypic slices. Clock performance of organotypic slices of liver (A–C) and SCN (D–F)
frommPER2Luc mice following treatment with 6 μM BMs90p or mock treatment with fresh
medium was monitored by real-time bioluminescence imaging. Treatment was performed
around the PER2::LUC trough (A, B: liver; ~CT5, D, E: SCN; ~CT1) or peak (C: liver; ~CT17,
F: SCN; ~CT13) phase. Note that reduction of peak bioluminescence after BMs90p-treatment
was only observed when slices were treated around the trough phase.
(EPS)
S3 Fig. Reduction of amplitudes in circadian rhythms in liver and SCN after BMs90p-treat-
ment. As S2 Fig, except that data were further normalized using maximum circadian peak
intensities over time. A reduction of rhythm amplitude (Fig 1Bb) after BMs90p-treatment was
calculated from detrended data by comparing averaged differences between the peak and
trough over 2 d before and after the treatment. Similarly, reduction of peak bioluminescence
(Fig 1Cb) after BMs90p-treatment was calculated from raw data (Fig 1Ca) by comparing aver-
aged peak differences over 2 d pre- and post-treatment.
(TIF)
S4 Fig. Reduction of Per2L-bioluminescence in SCN neurons after BMs90p-treatment. An
organotypic SCN slice frommPER2Luc mice was monitored by real-time bioluminescence
microscopy (LV200, Olympus, Japan). Cultures were treated with 6 μM BMs90p around
trough phase (CT2) as indicated. (A) Bioluminescence recordings of 24 different cell regions.
(B) Representative images of Per2L SCN slices around the trough (CT2) and peak phase
(CT14), recorded for 6 d. Fig 1Ca shows normalized, detrended plots.
(EPS)
S5 Fig. Restoration of circadian gene expression in CRY1/2-deficient MEFs by rhythmic
CRY1 expression. Cry1/2-/- MEFs, expressing the Per3-Luc clock reporter gene and either
CMV-promoter-driven GFP (A) or mCry1 promoter-driven Myc-CRY1 (B), were Dex-syn-
chronized and monitored by real-time bioluminescence recording. For each graph, curves
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represent detrended values, normalized against the maximum value (set as 1).
(EPS)
S6 Fig. CK2 subunits binds to BMAL1 and CRY1/2 proteins. (A) Differential binding of
CK2 subunits to the mammalian clock proteins in vitro. Purified bacterially expressed
GST-CK2α, α0, and β subunits (upper panel) were 1:1 mixed with in vitro translated 35S-methi-
onine labeled BMAL1, V5-CRY1, or V5-CRY2, affinity purified using glutathione Sepharose
beads. The precipitates were subjected to SDS-PAGE and visualized by autoradiography. (B)
CK2β forms complex with CRY1/2. Shown is a representative example of a coimmunoprecipi-
tation experiment with endogenous CK2β and CRY1 or CRY2 in BMAL1-deficient MEFs.
Lysates and CK2β- and CRY1/2- IPs were subjected to IB analysis for CK2β and CRY1/2.
(EPS)
S7 Fig. Circadian BMAL1–CK2β association shows inversed-phase to circadian CK2α-
mediated BMAL1-S90 phosphorylation.WT, Cry1/2−/−MEFs, and Cry1/2−/−MEFs stably
expressingmCry1 promoter-driven Myc-CRY1 or CMV-promoter-driven Myc-GFP (control)
were Dex-synchronized. BMAL1 and CK2β IPs and total lysates were subjected to IB analysis
for BMAL1, P-BMAL1-S90, CK2α/β, and CRY1/2, using PER1/actin as a loading control.
(EPS)
S8 Fig. Circadian BMAL1–CK2β binding rhythms in living cells. (A) Circadian interaction
between BMAL1–CK2β in Dex-synchronized ELucN-CK2β and McLuc1-BMAL1 expressing
U-2OS cells was monitored by the real-time Split Luc assay. Circadian profiles obtained in
three independent experiments (green, light blue, and dark blue) are shown. Data were normal-
ized by setting the value of the first peak as 1. (B) Prolonged circadian monitoring of the inter-
action between BMAL1 and CK2β in U-2OS cells transfected with pEBMulti-based episomal
type expression vectors suitable for longer term detection (Wako, Japan) for ELucN-CK2β and
McLuc1-BMAL1. Representative detrended/averaged circadian profiles (averaged Period = 25.8
h, Acrophase = 15.7 h, as determined using Cosinor and Acro software; http://www.circadian.
org/softwar.html) are shown with the maximum normalized values set as 1. (C) Analysis of
RREx3/CMV and CMV promoters, as used for the ectopic expression of BMAL1 and CK2β in
the Split Luc assay. Dex-synchronized U-2OS cells, expressing RREx3/CMV (for BMAL1 in
the split Luc vectors) or CMV (for CK2β in the split Luc vectors)-promoter driven luciferase
were monitored by real-time bioluminescence imaging. Circadian profiles (averaged values
from n = 3 experiments) were normalized, with the maximum value set as 1. Note that RREx3/
CMV-Luc activity did not show evident circadian oscillation.
(EPS)
S9 Fig. Ectopic expression of BMAL1 and CK2β from split Luc vectors does not affect
endogenous circadian phase. Dex-synchronized U-2OS cells, stably expressing Bmal1-pro-
moter driven luciferase in the absence (black line) or presence (blue line) of ELucN-CK2β and
McLuc1-BMAL1 (Split Luc assay for BMAL1–CK2β association; same dose as used in Fig 4C)
were monitored by real-time bioluminescence imaging. Circadian profiles (averaged values
from n = 5 experiments) were normalized, with the maximum value set as 1. Note that Split
Luc activity can be neglected because of the much higher Bmal1-luciferase activity.
(EPS)
S10 Fig. Acetylation-mediated BMAL1-Ser90 phosphorylation is not prerequisite for
BMAL1-Ser90 phosphorylation.Mutation of BMAL-Lys537, the CLOCK-mediated acetyla-
tion site, does not erase BMAL1-Ser90 phosphorylation. Bmal1−/−MEFs stably expressing
mBmal1 promoter-driven Myc-BMAL1-WT (wild type), Myc-BMAL1-K537R (CLOCK-
Circadian Oscillatory Mechanism for Mammalian Clock Protein Kinase
PLOS Biology | DOI:10.1371/journal.pbio.1002293 November 12, 2015 22 / 25
mediated acetylation site-deficient mutant) and CMV-promoter-driven Myc-GFP (control)
were Dex-synchronized. The supernatants from the cells at 22 h after treatment were subjected
to Myc-BMAL1 IP. IPs and lysates were subjected to IB analysis for Myc-BMAL1/GFP,
P-BMAL1-S90, Acetyl-BMAL1, CK2β, and CRY1/2.
(EPS)
S11 Fig. Nuclear dominant localization of P-BMAL1-S90.WTMEFs were synchronized
with dexamethasone and subsequently harvested at 4 h intervals. For each time point, BMA-
L1-IPs and lysates from the nuclear and cytoplasmic fractions (prepared as previously
described [38]) were subjected to IB analysis for P-BMAL1-S90 and BMAL1, using RNA poly-
merase II (Pol II) and actin as the loading controls. Red and black arrows indicate the position
of major P-BMAL1-S90 (~90 kDa) and unmodified BMAL1 (~70 kDa), respectively.
(EPS)
S12 Fig. Effect of CRY1 protein on the in vitro CK2α-mediated BMAL1-S90 kinase activity.
(A) Purified recombinant His-CRY1 protein expressed in High Five insect cells can bind to
BMAL1. His-CRY1 expressed in High Five cells was purified and detected by CBB-staining
and immunoblotting with anti-His antibody. By IB analysis for the His- immunoprecipitate
(His-IP) for the mixture of the purified GST-BMAL1 and His-CRY1, GST-BMAL1 and His-
CRY1 were detected with anti-BMAL1 and anti-His antibodies. Note that no apparent band
with higher molecular weight than His-CRY1 was detected in the CBB-stained gel. (B) His-
CRY1 does not show inhibitory effect on the in vitro BMAL1-S90 phosphorylation. CK2α-
mediated BMAL1-S90 kinase activity was measured by in vitro kinase assay with GST-BMAL1,
CK2α, and differential doses of His-CRY1 and CK2β proteins, under the procedure for Fig 2C.
(EPS)
S1 Movie. Effect of BMs90p-treatment on Per2L-rhythm in the SCN organotypic slice. An
organotypic slice of the SCN frommPER2Luc mice was monitored by real-time biolumines-
cence microscopy (LV200, Olympus, Japan). Cultures were treated with 6 μM BMs90p around
the trough phase (at time Zero after 2 d and 17 h) as indicated in Fig 1C and S4 Fig.
(MP4)
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